Clinical trial
Assessing the Effect of Natalizumab of Magnetic Resonance Imaging Measures of Blood Brain Barrier Permeability and Myelin Integrity
NCT05177718 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessing the Effect of Natalizumab of Magnetic Resonance Imaging Measures of Blood Brain Barrier Permeability and Myelin Integrity
- Lead sponsor
- Vanderbilt University Medical Center
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- September 16, 2022
- Completion date
- April 5, 2023
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.